Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Processa Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- +2 vs. Q1 2026
- Shares held
- 255.5K
- +77.8K (+43.8%) vs. Q1 2026
- Total value
- $498.3K
- +$49.9K (+11.1%) vs. Q1 2026
- New holders
- 4
- 3 more added
- Sold out
- 2
- 1 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $498.3K |
| Q1 2026 | 10 | $448.5K |
| Q4 2025 | 10 | $331.0K |
| Q3 2025 | 14 | $341.9K |
| Q2 2025 | 13 | $75.9K |
| Q1 2025 | 9 | $63.2K |
| Q4 2024 | 8 | $87.5K |
| Q3 2024 | 8 | $66.5K |
| Q2 2024 | 9 | $101.0K |
| Q1 2024 | 11 | $251.5K |
| Q4 2023 | 18 | $376.5K |
| Q3 2023 | 20 | $349.8K |
| Q2 2023 | 19 | $691.4K |
| Q1 2023 | 22 | $852.6K |
| Q4 2022 | 18 | $1.28M |
| Q3 2022 | 18 | $2.58M |
| Q2 2022 | 18 | $3.24M |
| Q1 2022 | 18 | $3.22M |
| Q4 2021 | 19 | $6.47M |
| Q3 2021 | 18 | $12.2M |
| Q2 2021 | 18 | $11.2M |
| Q1 2021 | 17 | $12.3M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Processa Pharmaceuticals, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Connective Capital Management, LLC | 85,274 | $163.7K | 0.12% | +14,538+20.6% | Added |
| Stonepine Capital Management, LLC | 55,000 | $105.6K | 0.08% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 22,090 | $42.4K | 0.00% | −2,818−11.3% | Reduced |
| Citadel Advisors LLC | 21,306 | $40.9K | 0.00% | +21,306 | New |
| StoneX Group Inc. | 11,437 | $29.6K | 0.00% | +11,437 | New |
| XTX Topco Ltd | 13,292 | $25.5K | 0.00% | +13,292 | New |
| Jane Street Group, LLC | 13,264 | $25.5K | 0.00% | +13,264 | New |
| Vanguard Capital Management LLC | 12,729 | $24.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 10,857 | $20.8K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7,794 | $15.0K | 0.00% | +5,263+207.9% | Added |
| Tower Research Capital LLC (TRC) | 2,499 | $4.80K | 0.00% | +1,581+172.2% | Added |
| Jones Financial Companies LLLP | 7 | $13 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −6−100.0% | Sold out |